Cargando…

Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site

PURPOSE: The purpose of this study was to investigate the clinical outcomes of bromfenac ophthalmic solution 0.09% once daily (QD) and nepafenac 0.1% ophthalmic suspension three times daily following cataract extraction with posterior chamber intraocular lens implantation, specifically looking at an...

Descripción completa

Detalles Bibliográficos
Autor principal:	Cable, Melissa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399390/ https://www.ncbi.nlm.nih.gov/pubmed/22815642 http://dx.doi.org/10.2147/OPTH.S32179

Ejemplares similares

Bromfenac 0.09% for the Treatment of Macular Edema Secondary to Noninfectious Uveitis
por: Saade, Joanna S., et al.
Publicado: (2021)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes
por: Song, Seok Hyeon, et al.
Publicado: (2020)

Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery
por: Nardi, M, et al.
Publicado: (2007)

Bromfenac 0.09% bioavailability in aqueous humor, prophylactic effect on cystoid macular edema, and clinical signs of ocular inflammation after phacoemulsification in a Mexican population
por: Palacio, Claudia, et al.
Publicado: (2016)

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
por: Toyos, Melissa M.
Publicado: (2019)

Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%
por: Hariprasad, Seenu M, et al.
Publicado: (2009)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
por: Wang, Xiao Jing, et al.
Publicado: (2011)

Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I–III for clinical signs on ocular inflammation
por: Chávez-Mondragón, Eduardo, et al.
Publicado: (2019)

The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery
por: Jung, Ji Won, et al.
Publicado: (2015)

Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose
por: Silverstein, Steven M.
Publicado: (2019)

Erbium-doped (Pb(0.9)-Er(0.01)-Zr(0.09)) and (Pb(0.9)-Er(0.01)-Zr(0.045)-Ti(0.045)) nano-crystalline films and nano-rods ceramic synthesis by sol–gel technique for energy-storage application
por: Ibrahim, F. A., et al.
Publicado: (2023)

Comparison of the efficacy of Diclofenac 0.1% and Nepafenac 0.1% on anterior chamber cells in patients undergoing cataract surgery: A prospective clinical practice trial
por: Ahmad, Adnan, et al.
Publicado: (2023)

Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification
por: Bardoloi, Narayan, et al.
Publicado: (2022)

KMg(0.09)Fe(1.91)(PO(4))(2)
por: Yatskin, Michael M., et al.
Publicado: (2012)

QD0 Design
por: Modena, Michele
Publicado: (2013)

QD0 Design
por: Modena, Michele
Publicado: (2013)

Comparison between 0.1% Nepafenac and 1% Prednisolone Eye Drop in Postoperative Management Following Micro-incisional Cataract Surgery
por: Sarkar, Sandip, et al.
Publicado: (2021)

Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema
por: Giarmoukakis, Athanassios K, et al.
Publicado: (2020)

Effects of Topical Prostaglandin Analog on Macular Thickness Following Cataract Surgery with Postoperative Topical Bromfenac Treatment
por: Park, Kee Sup, et al.
Publicado: (2020)

Comparison of preoperative nepafenac (0.1%) and flurbiprofen (0.03%) eye drops in maintaining mydriasis during small incision cataract surgery in patients with senile cataract: A randomized, double-blind study
por: Sarkar, Saumya, et al.
Publicado: (2015)

Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
por: Singh, Rishi P, et al.
Publicado: (2017)

Structure properties and dielectric relaxation of Ca(0.1)Na(0.9)Ti(0.1)Nb(0.9)O(3) ceramic
por: Ghoudi, Hanen, et al.
Publicado: (2019)

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John A, et al.
Publicado: (2021)

Evaluation effectiveness of 0.1% nepafenac on injection-related pain in patients undergoing intravitreal Ozurdex injection
por: Ogurel, Tevfik, et al.
Publicado: (2019)

Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients
por: Numaga, Jiro
Publicado: (2011)

Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy
por: Singh, Rishi, et al.
Publicado: (2012)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

CLIC QD0 "Short Prototype" Status
por: Modena, Michele
Publicado: (2012)

Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review
por: Sheppard, John D
Publicado: (2016)

Aliovalent-doped sodium chromium oxide (Na(0.9)Cr(0.9)Sn(0.1)O(2) and Na(0.8)Cr(0.9)Sb(0.1)O(2)) for sodium-ion battery cathodes with high-voltage characteristics
por: Park, Woon Bae, et al.
Publicado: (2020)

Crystal structure of the cubic double-perovskite Sr(2)Cr(0.84)Ni(0.09)Os(1.07)O(6)
por: Chen, Jie, et al.
Publicado: (2022)

Topical nepafenac in the treatment of diabetic macular edema
por: Callanan, David, et al.
Publicado: (2008)

Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy
por: Nagpal, Manish, et al.
Publicado: (2014)

Considerations for a QD0 with Hybrid Technology in ILC
por: Modena, M, et al.
Publicado: (2014)

Topical nepafenac for prevention of post-cataract surgery macular edema in diabetic patients: patient selection and perspectives
por: Yüksel, Bora, et al.
Publicado: (2017)

Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD
por: Wyględowska-Promieńska, Dorota, et al.
Publicado: (2015)

Flexible Lead-Free Piezoelectric Ba(0.94)Sr(0.06)Sn(0.09)Ti(0.91)O(3)/PDMS Composite for Self-Powered Human Motion Monitoring
por: Deng, Lin, et al.
Publicado: (2023)

Influence of Cobalt Doping on the Physical Properties of Zn(0.9)Cd(0.1)S Nanoparticles
por: Singhal, Sonal, et al.
Publicado: (2009)

Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg ‐levonorgestrel 0.09 mg for dysmenorrhea: A placebo‐controlled, double‐blind, randomized trial
por: Harada, Tasuku, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_it3shlrmf1843rvn8j4keosbrg